Abstract Number: 2591 • ACR Convergence 2024
Lupus-Related Reproductive Health Experiences and Needs of Women of Childbearing Age: A Qualitative Study
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune condition that primarily affects women of childbearing age, with many patients being diagnosed during puberty. Contraception…Abstract Number: 0418 • ACR Convergence 2024
Improving Documentation of Contraception and Pregnancy Intention in Rheumatology Practice
Background/Purpose: Prior studies of RISE Registry found 9-11% of women of reproductive age with contraception documentation. We sought to identify and assess methods to increase contraception documentation…Abstract Number: 0442 • ACR Convergence 2024
Anti-U1-RNP Related Pregnancy Loss in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) affects women of childbearing years and confers an increased risk of pregnancy complications. Risk of adverse events in pregnancy is…Abstract Number: 0809 • ACR Convergence 2024
The Utility of the sFlt1:PlGF Ratio to Rule out and Predict Preeclampsia in Women with Lupus
Background/Purpose: Women with SLE have high rates of preeclampsia caused by poor placental vascularization. The FDA recently approved the ratio of two angiogenic factors, soluble…Abstract Number: 0422 • ACR Convergence 2024
Greater Use of Assisted Reproductive Techniques but Comparable Obstetric Morbidity in a Population of Women with Spondyloarthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys
Background/Purpose: Spondyloarthritis (SpA) regularly affects women of childbearing age1. A higher obstetric morbidity in women with SpA is suggested in the literature in several countries,…Abstract Number: 0443 • ACR Convergence 2024
Significance of anti-Ro52 Antibody in Pregnancy Complicated with Anti-SS-A Antibody Positive Rheumatic Disease Patients
Background/Purpose: Anti-SS-A antibodies are associated with neonatal lupus erythematosus and congenital heart block (CHB). Ro/SS-A autoantigen is comprised of 52kDa Ro (Ro52) and 60kDa Ro…Abstract Number: 0810 • ACR Convergence 2024
Glucocorticoids in Pregnancy and Lactation: Results of the Systematic Review Informing the EULAR Task Force on Antirheumatic Drugs in Reproduction, Pregnancy and Lactation
Background/Purpose: The management of women with musculoskeletal disorders during pregnancy and lactation presents many challenges. Since the first EULAR points to consider for the use…Abstract Number: 0466 • ACR Convergence 2023
Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study
Background/Purpose: There are limited data on the impact of the postpartum period (PP) on the activity of inflammatory rheumatic disorders (IRD), and the data available…Abstract Number: 1003 • ACR Convergence 2023
A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis
Background/Purpose: Rheumatic disorders frequently affect women of childbearing age. These diseases and medications used to treat them can have adverse effects on fertility and fetuses.…Abstract Number: 1682 • ACR Convergence 2023
Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block
Background/Purpose: The management of fetuses exposed to maternal anti-SSA/Ro autoantibodies is challenging as the clinician weighs the rarity of fetal atrioventricular block (AVB) against the…Abstract Number: 0467 • ACR Convergence 2023
Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome
Background/Purpose: Autoimmune rheumatic diseases (ARD) and antiphospholipid syndrome (APS) are autoimmune conditions with increased risks of cardiovascular complications as well as negative pregnancy consequences. We…Abstract Number: 1345 • ACR Convergence 2023
Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy
Background/Purpose: Abatacept is approved for the treatment of moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis. However, there are limited data on the safety…Abstract Number: 1683 • ACR Convergence 2023
Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO
Background/Purpose: Project ECHO™ in an education model that links experts with community providers through a series of video teleconferences. Each conference involves a brief didactic…Abstract Number: 0468 • ACR Convergence 2023
Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes
Background/Purpose: Increased rates of adverse pregnancy outcomes (APOs) have been reported in association with rheumatologic diseases such as systemic lupus erythematosus (SLE), dermatomyositis (DM), and…Abstract Number: 1347 • ACR Convergence 2023
Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination
Background/Purpose: It is important to control disease activity during pregnancy in women with rheumatic diseases because its exacerbation is associated with increased adverse pregnancy outcomes.…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 19
- Next Page »